Sign up to save your podcasts
Or
Share 🧬 Blocking TGF-β, Boosting Function, Sotatercept's Early Advantage inPAH
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
🧬 Blocking TGF-β, Boosting Function, Sotatercept's Early Advantage inPAH
🚨 Just out in NEJM! In the Phase 3 HYPERION trial, adding sotatercept early in pulmonary arterial hypertension (PAH) slashed clinical worsening risk by 76% vs placebo (HR 0.24, P
💡 Benefits appeared after just 3 doses, with improved 6-min walk, NT-proBNP, and risk scores. Most AEs were mild (epistaxis, telangiectasia).
📊 A game-changer in early PAH therapy. NNT = 5 over 12 months.
🔗 #Cardiology #PulmonaryHypertension #Sotatercept #NEJM #PrecisionMedicine #ClinicalTrials #RightHeart #TGFb #REVEAL #COMPERA
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
🚨 Just out in NEJM! In the Phase 3 HYPERION trial, adding sotatercept early in pulmonary arterial hypertension (PAH) slashed clinical worsening risk by 76% vs placebo (HR 0.24, P
💡 Benefits appeared after just 3 doses, with improved 6-min walk, NT-proBNP, and risk scores. Most AEs were mild (epistaxis, telangiectasia).
📊 A game-changer in early PAH therapy. NNT = 5 over 12 months.
🔗 #Cardiology #PulmonaryHypertension #Sotatercept #NEJM #PrecisionMedicine #ClinicalTrials #RightHeart #TGFb #REVEAL #COMPERA
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
893 Listeners
The Curbsiders Internal Medicine Podcast
3,374 Listeners
The Mel Robbins Podcast
21,500 Listeners